Document Detail

Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?
MedLine Citation:
PMID:  19546178     Owner:  NLM     Status:  MEDLINE    
To increase the survival rate of patients with acute superior mesenteric artery thromboembolism (ASMAT) treated by catheter thrombolysis, we examined the effects of delivering edaravone and asialoerythropoietin, agents with tissue-protective activities, using a rabbit autologous fibrin clot ASMAT model. Japanese white rabbits (n=32) were randomly separated into four equal groups. 45 min after introducing autologous fibrin clot, Group U received urokinase and heparin; Group E received urokinase and heparin plus edaravone; Group A received urokinase and heparin plus asialoerythropoietin; and Group EA received urokinase, heparin and edaravone plus asialoerythropoietin via a catheter. The intestines were removed 6 h later and intestinal mucosal damage was scored using the Park's injury score. Survival time was assessed. Average mucosal injury was 5.78+/-1.52 (Group U), 2.88+/-0.72 (Group E), 1.90+/-1.23 (Group A) and 1.18+/-1.25 (Group EA). The degree of mucosal injury was significantly lower in Group EA than in Groups U and E (p<0.05). Conversely, there was no significant difference between Group A and Group EA, or between Group A and Group E. The survival times were 31.50+/-13.30 h (Group U), 51.00+/-24.74 h (Group E), 48.00+/-16.97 h (Group A) and 82+/-51.07 h (Group EA); the difference among the four groups was not significant. In conclusion, the concomitant administration of asialoerythropoietin and edaravone reduced mucosal membrane injury significantly compared with edaravone alone. However, to improve the survival of ASMAT rabbit models, the delivery of an appropriate dose of asialoerythropoietin is required, together with the development of methods to assess peripheral recanalisation.
A Sonoda; N Nitta; A Seko; S Ohta; S Takemura; T Sugimoto; T Uzu; Y Yokomaku; M Takahashi; A Kashiwagi; K Murata
Related Documents :
18452778 - Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bi...
18005758 - Best poster award. a comparison of thromboembolic and bleeding events following laparos...
9684788 - Use of a heparin nomogram for treatment of patients with venous thromboembolism in a co...
22475108 - Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associat...
16429858 - A complex class ii case with crowding and missing teeth.
20299178 - Quality of life before surgery is a predictive factor for satisfaction among patients u...
Publication Detail:
Type:  Journal Article     Date:  2009-06-22
Journal Detail:
Title:  The British journal of radiology     Volume:  83     ISSN:  1748-880X     ISO Abbreviation:  Br J Radiol     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-08     Completed Date:  2010-05-18     Revised Date:  2013-02-19    
Medline Journal Info:
Nlm Unique ID:  0373125     Medline TA:  Br J Radiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  129-32     Citation Subset:  AIM; IM    
Department of Radiology, Shiga University of Medical Science, Shiga, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipyrine / administration & dosage,  analogs & derivatives*,  pharmacology
Asialoglycoproteins / administration & dosage*,  pharmacology
Disease Models, Animal
Drug Combinations
Erythropoietin / administration & dosage,  analogs & derivatives*,  pharmacology
Fibrinolytic Agents / therapeutic use
Free Radical Scavengers / administration & dosage*,  pharmacology
Heparin / therapeutic use
Injections, Intra-Arterial
Intestinal Mucosa / pathology
Mesenteric Artery, Superior
Mesenteric Vascular Occlusion / complications*,  drug therapy,  mortality
Random Allocation
Reperfusion Injury / etiology,  pathology,  prevention & control*
Survival Rate
Thromboembolism / complications*,  drug therapy,  mortality
Urokinase-Type Plasminogen Activator / therapeutic use
Reg. No./Substance:
0/Asialoglycoproteins; 0/Drug Combinations; 0/Fibrinolytic Agents; 0/Free Radical Scavengers; 0/asialoerythropoietin; 11096-26-7/Erythropoietin; 60-80-0/Antipyrine; 9001-31-4/Fibrin; 9005-49-6/Heparin; EC Plasminogen Activator; S798V6YJRP/phenylmethylpyrazolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancement pattern of the normal facial nerve at 3.0 T temporal MRI.
Next Document:  Incidental breast lesions detected on CT: what is their significance?